Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT05193136
Recruiting Observational

Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease

NCT05193136 · tracked via the Priya Life Science Japan tracker
Sponsor
National Hospital Organization Minami Kyoto Hospital
Phase
Observational
Started
2021-12-10
Last updated
2023-03-28

Condition(s) studied

Sleep HygieneSarcopeniaCognitive FunctionCOPDIPF

Study summary

We aim to clarify the relationship between sleep hygiene and the onset of sarcopenia or cognitive dysfunction using sleep time, arousal, and sleep quality as indicators in COPD or IPF patients, and clarify the effects of sleep hygiene on disease progression and life prognosis.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subjects with COPD or IPF. Exclusion Criteria: * Subjects who have been hospitalized for exacerbation of respiratory failure within 1 month of study participation * Subjects who have already been diagnosed with sarcopenia or cognitive dysfunction * Subjects receiving long-term oxygen therapy (LTOT) or non-invasive ventilation therapy (NIV) * Subjects with obstructive sleep apnea who are indicated for continuous positive airway pressure (CPAP) * Subjects with severe complications such as cardiovascular disease, liver disease, renal disease, malignancy, and neurological disease.

Primary outcome measure(s)

  • Relationship between sleep time at study enrollment and onset of sarcopenia during follow-up period — Two years

Trial sites (1)

FacilityCityRegionStatus
National Hospital Organization Minami Kyoto Hospital Jōyō Kyoto Recruiting

Other trials for the same condition

Zephyr Valve Japan Post-Marketing Surveillance Recruiting
Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy Starting soon
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants Starting soon
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS Active, not recruiting
Lung Health of Early COPD: A Multi-center Cohort Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05193136 on ClinicalTrials.gov ↗ ← All trials in Japan